Semaglutide 2.4 mg Real-world Risk Reduction of Cardiometabolic Comorbidities and Improvement in Biomarkers among Patients with Overweight or Obesity (SMILE)

Disease Areas
Congresses
Scientific Publications
IME

Search Science Hub

Register Login

My Account

Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

Congresses
AHA 2025
Semaglutide 2.4 mg Real-world Risk Reduction of Cardiometabolic Comorbidities and Improvement in Biomarkers among Patients with Overweight or Obesity (SMILE)